Conference Coverage

Intranasal naloxone promising for type 1 hypoglycemia


 

REPORTING FROM ADA 2018

The study subjects were men, 43 years old, on average, with a mean body mass index of 26 kg/m2.

The investigators didn’t have any disclosures, and there was no industry funding for the work.

SOURCE: Aleksic S et al. ADA 2018, Abstract 10-LB.

Pages

Recommended Reading

CANVAS: Canagliflozin improved renal outcomes in diabetes
Clinician Reviews
SUSTAIN-7: GLP-1 receptor agonists effective in elderly
Clinician Reviews
GDM, subsequent diabetes predictive of later renal damage
Clinician Reviews
Patient adjustments needed for closed-loop insulin delivery
Clinician Reviews
Intensive treatment for T2D pays off in the long run
Clinician Reviews
Diabetes in the elderly: Matching meds to needs
Clinician Reviews
Study questions canagliflozin amputation risk, but concerns remain
Clinician Reviews
High risk of low glucose? Hospital alerts promise a crucial heads-up
Clinician Reviews
Chronic kidney disease is 40% more common in T2DM than T1DM
Clinician Reviews
Study spotlights risk factors for albuminuria in youth with T2DM
Clinician Reviews